Biosensors and Nanotheranostics

1. Introduction

Nanomedicine, broadly defined as the application of nanotechnology to the prevention, diagnosis and treatment of disease, has changed character over the past three decades (Boisseau & Loubaton, 2011; Fornaguera & García-Celma, 2017). Early work focused on reformulating existing drugs into systemic carriers; current research is closer to molecular engineering, in which the size, surface and internal architecture of a particle are designed around a specific biological problem. The underlying rationale, however, has stayed the same. At dimensions of roughly 1-100 nm, materials acquire physicochemical behaviour that bulk matter lacks, including very high surface-area-to-volume ratios and surfaces whose chemistry can be tuned almost at will (Marriam & Khalid, 2026).

Those properties were first put to work against the familiar weaknesses of conventional therapeutics. Since liposomal formulations gained regulatory approval in the mid-1990s, the field has concentrated on poor aqueous solubility, indiscriminate biodistribution, rapid clearance from the circulation and the off-target toxicities that follow from all three (Payam & Lionadi, 2026). Fornaguera and García-Celma (2017) had already framed the next logical step as personalisation: if a carrier can be engineered, it can, in principle, be engineered for a particular patient.

For much of this history, tumour targeting rested on the Enhanced Permeability and Retention (EPR) effect, the tendency of nanoparticles to leak through abnormal tumour vasculature and linger because lymphatic drainage is poor (Marriam & Khalid, 2026). Passive accumulation of this kind was once treated as a near-universal delivery route. Accumulating clinical experience has been less encouraging: vascular permeability varies enormously between patients and even within a single tumour, so passive accumulation alone proved an unreliable foundation (Marriam & Khalid, 2026; Payam & Lionadi, 2026).

That disappointment prompted a conceptual shift toward active targeting and what has been termed chemo-biochemical convergence (Marriam & Khalid, 2026; Payam & Lionadi, 2026). The idea is to join synthetic chemical engineering, such as precise scaffold synthesis, steric PEGylation and cleavable linkers, with the orchestration that biology already performs (Marriam & Khalid, 2026). Decorating a carrier surface with antibodies, peptides or aptamers lets it recognise receptors that diseased cells overexpress, while microenvironment-responsive designs withhold their cargo until they encounter an acidic pH, a reducing redox potential, a particular enzyme or local heat (Marriam & Khalid, 2026). Releasing drug in a staged, conditional way is what raises the therapeutic index while sparing healthy tissue (Labhade & Pihulkar, 2026; Marriam & Khalid, 2026).

Alongside the carriers themselves, a second line of advance has reshaped how biological events are measured in the first place (Preetam, 2026; Reddy et al., 2024). Conventional in vitro assays tend to be destructive and record only endpoints, so transient events and continuous metabolic flux slip past them (Preetam, 2026). Microfluidic organ-on-a-chip (OoC) platforms were developed partly in response, recreating tissue architecture, cellular interfaces and perfusion under flow (Preetam, 2026).

Placing quantum biosensors inside those chips adds a physics-based read-out (Preetam, 2026). Semiconductor quantum dots, nitrogen-vacancy (NV) centres in diamond and atom-based magnetometers can report signals label-free, at sub-cellular resolution and with picotesla magnetic or millikelvin thermal sensitivity, which makes it possible to follow electrophysiological activity in neural or cardiac microtissue without touching it (Preetam, 2026). On the body rather than the bench, Micro-Electro-Mechanical Systems (MEMS) and their biological counterparts (BioMEMS) underpin point-of-care testing, implantable sensors and smart transdermal delivery, linking continuous monitoring to targeted release (Marinescu et al., 2025; Reddy et al., 2024).

Personalised care, though, needs more than hardware; it needs the data layer that interprets it (Akwo et al., 2026; Deshmukh & Yadav, 2025). Multi-omics profiling across genomics, transcriptomics, proteomics and metabolomics now yields detailed molecular portraits of individual patients (Akwo et al., 2026). Such portraits let carriers be designed rationally, with ligands and cargo, whether a chemotherapeutic, an siRNA or CRISPR-Cas machinery, matched to the pathways that are actually dysregulated (Akwo et al., 2026; Haque et al., 2025).

Artificial intelligence (AI), machine learning (ML) and digital twins extend this still further (Chowdhury et al., 2026; Deshmukh & Yadav, 2025). Algorithms can suggest a particle's ideal size, charge, ligand density and drug loading from a patient's biological profile (Bhukta et al., 2026; Laddha et al., 2026), and when they are fed live signals from wearable BioMEMS, implantable nanosensors or electrochemical aptamer-based devices, digital twin models can simulate that patient's pharmacokinetics and let clinicians adjust dosing and anticipate response (Chowdhury et al., 2026; Laddha et al., 2026).

These ideas are not purely theoretical, and they show most clearly in oncology and in neurodegenerative disease (Bhukta et al., 2026; Haque et al., 2025). In cancer, theranostic nanocarriers combine targeted delivery with non-invasive imaging such as MRI, PET or near-infrared fluorescence, so that therapy and monitoring proceed together (Akwo et al., 2026; Marriam & Khalid, 2026). Some designs exploit metabolic weaknesses directly: copper-based nanoplatforms, for instance, trigger cuproptotic death in hepatocellular carcinoma by overwhelming the mitochondrial copper economy of the tumour (Labhade & Pihulkar, 2026).

In the central nervous system, the blood-brain barrier (BBB) is the recurring obstacle, whether the target is Alzheimer's disease or glioblastoma (Haque et al., 2025; Mazahir, 2026). Surface-engineered carriers, among them mesoporous silica nanoparticles (MSNs), lipid nanoparticles (LNPs) and biomimetic membrane-coated constructs, can cross it by receptor-mediated transcytosis and deposit chemotherapeutics, neuroprotective agents or gene-editing tools in the brain parenchyma itself (Bhukta et al., 2026; Mazahir, 2026).

It would be misleading to present all of this as settled. Preclinical promise has consistently outrun clinical delivery, held back by technical, biological and regulatory obstacles (Marriam & Khalid, 2026; Payam & Lionadi, 2026). A protein corona forms the moment a particle meets blood; nanotoxicity over the long term is poorly understood; large-scale synthesis introduces batch-to-batch variability; and regulatory frameworks struggle with products that are part drug and part device (Payam & Lionadi, 2026). Closing the gap between bench and bedside will require reproducible chemistry, manufacturing and controls (CMC), standardised safety testing and sensible patient stratification (Haque et al., 2025; Payam & Lionadi, 2026).

To bring these strands together, this review evaluates the current state of next-generation nanomedicine and the technologies that support personalised care. Its specific objectives are: (1) to analyse the shift from passive accumulation to active, chemo-biochemical and stimulus-responsive delivery (Marriam & Khalid, 2026; Payam & Lionadi, 2026); (2) to assess emerging physical vectors, namely quantum biosensors, OoC platforms, BioMEMS and wearable or implantable devices, and their role in real-time monitoring (Preetam, 2026; Reddy et al., 2024); (3) to examine how multi-omics, AI and digital twins drive predictive design and dynamic personalisation (Akwo et al., 2026; Chowdhury et al., 2026; Deshmukh & Yadav, 2025); (4) to review applications in oncology and neurodegenerative disease (Bhukta et al., 2026; Haque et al., 2025; Labhade & Pihulkar, 2026; Mazahir, 2026); and (5) to identify bottlenecks in toxicity, protein corona dynamics, manufacturing and regulation, and to outline a translational roadmap (Haque et al., 2025; Payam & Lionadi, 2026).

2. Convergent Nanomedicine Combining Smart Carriers, Quantum Biosensing, and Digital Twins for Precision Therapy

2.1 The paradigmatic shift: from passive accumulation to chemo-biochemical convergence

For decades, cancer nanomedicine leaned heavily on the Enhanced Permeability and Retention (EPR) effect to carry nanoscale therapeutics into solid tumours (Marriam & Khalid, 2026). The concept was appealing in its simplicity: leaky, disordered tumour vasculature combined with impaired lymphatic drainage should let nanoparticles enter and stay, giving a universal gateway for delivery (Akwo et al., 2026; Payam & Lionadi, 2026). Experience has complicated that picture. Clinical data and quantitative meta-analyses show that the EPR effect varies markedly between patients and across regions of the same tumour (Chowdhury et al., 2026; Payam & Lionadi, 2026). Elevated interstitial fluid pressure of roughly 10-40 mmHg, dense extracellular matrix and uneven perfusion all restrict extravasation, so that the dose actually reaching the tissue is often below 1-8% of what was injected per gram (Akwo et al., 2026; Payam & Lionadi, 2026).

Confronted with those anatomical limits, the field reoriented toward chemo-biochemical convergence, an engineering philosophy that fuses synthetic design with biological recognition (Marriam & Khalid, 2026). Rather than relying on long circulation alone, modern platforms carry surface-grafted ligands, such as monoclonal antibodies, targeting peptides and nucleic acid aptamers, that bind selectively to overexpressed receptors (Marriam & Khalid, 2026; Payam & Lionadi, 2026). Convergence also encompasses stimulus-responsive design (Marriam & Khalid, 2026). By building in labile chemistry, for example hydrazone, imine or disulfide bonds, or phase-changing polymers, a carrier can stay sterically stable in the circulation yet cleave rapidly when it meets an acidic endosome, a high glutathione (GSH) concentration or a specific enzyme (Laddha et al., 2026; Marriam & Khalid, 2026). Pairing active recognition with spatially controlled release in this way reduces off-target toxicity while concentrating drug where it is needed (Marriam & Khalid, 2026). Table 1 summarises how these targeting and release strategies have evolved and the engineering

Figure 1. The paradigm shift from passive accumulation to chemo-biochemical convergence in nanomedicine. Schematic contrasting three generations of tumour-targeting strategy. (A) Passive targeting relies on the Enhanced Permeability and Retention effect, in which size-optimised, PEGylated carriers accumulate through leaky vasculature and poor lymphatic drainage, typically delivering less than 1-8% of the injected dose per gram of tissue. (B) Active cellular targeting adds surface ligands (antibodies, Fab fragments, RGD peptides, aptamers) that bind overexpressed receptors such as HER2, EGFR, integrins and the transferrin receptor, improving internalisation but remaining vulnerable to protein-corona masking. (C) Chemo-biochemical convergence integrates a stealth scaffold, biological ligand and cleavable linker in one hierarchical construct that negotiates successive biological barriers. The lower panels show the stimulus-responsive gates (pH, redox, enzymatic and external triggers) built into convergent carriers to release payload on demand, raising the therapeutic index at the cost of synthetic and manufacturing complexity.

Figure 2. Physical and micro-engineered vectors for continuous, label-free biomedical monitoring. Integrated view of the hardware that links tissue- and body-level physiology to digital health data. On the left, a hybrid quantum-organ-on-a-chip substrate combines a perfused microchannel (50-500 micrometres) with two quantum sensing modalities: nitrogen-vacancy diamond magnetometry, operating by optically detected magnetic resonance near 2.87 GHz to record action potentials contactlessly at picotesla sensitivity and sub-100 nm resolution, and semiconductor quantum dots (2-20 nm) that map local pH, oxygen and millikelvin thermal gradients by excitonic emission and FRET. On the right, BioMEMS and epidermal electronics capture ECG, EEG, EMG and sweat or interstitial-fluid biomarkers and drive closed-loop transdermal delivery. Both domains feed a shared Internet of Bodies data layer that supports remote monitoring, predictive analytics and digital-twin updating, while raising cybersecurity and privacy concerns.

trade-offs each entails, and Figure 1 depicts the overall progression.

2.2 Micro-engineered and physical vectors: quantum biosensing, organ-on-a-chip and BioMEMS

A parallel current of work concerns measurement, and here micro- and nano-engineering are reshaping diagnostics, disease modelling and physiological tracking (Marinescu et al., 2025; Preetam, 2026). Endpoint biochemical assays and fluorescence microscopy, the traditional tools, are destructive, prone to photobleaching and blind to transient dynamics (Preetam, 2026). Microfluidic organ-on-a-chip (OoC) platforms were conceived to do better, recreating functional tissue interfaces, three-dimensional cell-matrix interactions and biomimetic perfusion under controlled shear (Preetam, 2026).

Embedding quantum biosensors in those chips supplies a continuous, label-free read-out (Preetam, 2026). Sensors of this class, including nitrogen-vacancy (NV) centres in diamond, semiconductor quantum dots and atom-based magnetometers, exploit quantum coherence, spin states and excitonic confinement to register biological signals at sub-cellular resolution (Preetam, 2026). NV-centre magnetometry, operating through optically detected magnetic resonance (ODMR) near 2.87 GHz, can pick up picotesla-scale magnetic fluctuations from action potentials in cardiac or neural microtissue without any electrode contact or change in impedance (Preetam, 2026). Quantum dots dispersed in the matrix, meanwhile, report local pH, redox state and millikelvin thermal gradients through shifts in excitonic emission, mapping metabolic heterogeneity across tumour-on-chip models (Preetam, 2026).

Beyond the chip, Micro-Electro-Mechanical Systems (MEMS) and BioMEMS act as the physical link between a patient's physiology and digital monitoring, under what has been called the Internet of Bodies (IoB) (Marinescu et al., 2025; Reddy et al., 2024). Flexible, skin-conformal bioelectronics, including graphene- and carbon-nanotube-based electronic tattoos, continuously capture electroencephalogram (EEG), electromyogram (EMG) and metabolic data from sweat or interstitial fluid (Akwo et al., 2026; Marinescu et al., 2025). Coupled to MEMS micro-pumps and microneedle arrays, these devices can close the loop, adjusting transdermal dosing in response to the signals they record (Marinescu et al., 2025; Reddy et al., 2024). Figure 2 and Table 2 set out the architecture, sensing capabilities and translational readiness of these physical vectors.

2.3 Computational paradigms: multi-omics, artificial intelligence and digital twins

If the first two currents are chemical and physical, the third is computational, and it is what ties the physical carriers to systems biology (Akwo et al., 2026; Chowdhury et al., 2026). Multi-omics profiling across genomics, transcriptomics, proteomics and metabolomics builds a molecular map of the alterations that define a disease (Akwo et al., 2026). Proteomic data on overexpressed receptors guide ligand choice, while transcriptomic signatures inform RNA-responsive carriers that release siRNA or CRISPR-Cas cargo only when they recognise a specific oncogenic transcript (Akwo et al., 2026; Bhukta et al., 2026).

On top of this, AI and ML are displacing trial-and-error from formulation work (Deshmukh & Yadav, 2025). Models trained on large libraries predict hydrodynamic diameter, zeta potential, encapsulation efficiency and ligand orientation, and they describe non-linear release kinetics and particle-membrane interactions well enough to narrow preclinical screening considerably (Deshmukh & Yadav, 2025; Laddha et al., 2026). Digital Twin (DT) technology then builds on those predictions (Chowdhury et al., 2026; Deshmukh & Yadav, 2025). A medical digital twin is a continuously updated virtual replica of a patient, assembled from longitudinal records, genomic data, imaging and live BioMEMS streams (Chowdhury et al., 2026). By coupling physiologically based pharmacokinetic (PBPK) models with hybrid ML, a twin can simulate nanoparticle transport, extravasation, biodistribution and clearance, letting clinicians test dosing regimens and toxicity in silico before anything is administered (Chowdhury et al., 2026). These computational frameworks, with their strengths and limitations, are compared in Table 3 and illustrated in Figure 3.

2.4 Disease-specific applications: precision oncology and central nervous system therapeutics

The value of all this converged technology is clearest where it is applied, and two domains stand out: oncology and central nervous system (CNS) disease (Bhukta et al., 2026; Labhade & Pihulkar, 2026; Mazahir, 2026). In oncology, multifunctional carriers embody theranostics, carrying a therapeutic agent and an imaging agent,

Table 1. Evolution of targeting strategies and stimulus-responsive release mechanisms in nanomedicine. The table traces the progression from passive EPR-based accumulation through active cellular targeting to fully convergent, stimulus-responsive platforms. For each paradigm it summarises the chemical and structural engineering involved, the biological target or physiological trigger exploited, the principal efficacy and safety advantages, and the key limitations together with the engineering solutions proposed to overcome them. Primary supporting sources are listed in the final column.

Table 2. Physical and bio-engineering vectors: microfluidics, quantum biosensors, BioMEMS and the Internet of Bodies. The table compares the main hardware platforms that enable real-time, label-free biomedical monitoring. For each platform it describes the physical working principle and architecture, the primary sensing or operational capabilities, the biomedical application domain, and the comparative advantages and approximate technology-readiness level (TRL). Primary supporting sources appear in the final column.

perhaps superparamagnetic iron oxide for MRI, a radionuclide for PET or a fluorophore for optical imaging, in a single construct (Bhukta et al., 2026; Marriam & Khalid, 2026). Nanomedicine is also opening metabolic death pathways that cytotoxic drugs do not reach, cuproptosis among them, a copper-dependent, non-apoptotic form of cell death (Labhade & Pihulkar, 2026). In hepatocellular carcinoma (HCC), where cells show altered copper handling and heavy mitochondrial dependence, copper-based nanoplatforms such as copper sulfide, copper oxide and metal-organic frameworks deliver a targeted copper overload (Labhade & Pihulkar, 2026). Once released intracellularly, copper ions bind the lipoylated proteins of the tricarboxylic acid (TCA) cycle, particularly DLAT, provoking proteotoxic stress, loss of iron-sulfur cluster proteins and selective mitochondrial collapse (Labhade & Pihulkar, 2026).

In glioblastoma multiforme (GBM) and Alzheimer's disease, the limiting step is almost always the blood-brain barrier (Bhukta et al., 2026; Mazahir, 2026). Surface-engineered carriers, including MSNs, cationic LNPs and biomimetic membrane-coated constructs, cross it by receptor-mediated transcytosis aimed at transferrin, lactoferrin or low-density lipoprotein receptors (Mazahir, 2026). Through that route they can place chemotherapeutics such as temozolomide, neuroprotective compounds or mRNA-based gene-editing tools directly in the parenchyma, improving survival in preclinical models (Mazahir, 2026). Figure 4 and Table 4 summarise these applications together with the bottlenecks that still separate them from the clinic.

2.5 Translational bottlenecks: protein corona dynamics, manufacturing scale-up and regulation

For all the preclinical momentum, translation remains hard, and the obstacles are technical, biological and regulatory at once (Akwo et al., 2026; Marriam & Khalid, 2026). As soon as a particle enters the bloodstream, plasma proteins adsorb onto it to form a dynamic protein corona (Akwo et al., 2026; Chowdhury et al., 2026). That corona reshapes the particle's effective identity, hides its targeting ligands, invites premature clearance by the mononuclear phagocyte system (MPS) and alters where it ends up, which is why corona formation really ought to be assessed in each patient's own plasma (Akwo et al., 2026; AlSuhaimi et al., 2026).

Manufacturing is a second, less glamorous barrier. Moving from microgram bench quantities to kilogram-scale Good Manufacturing Practice (GMP) production is far from trivial (Akwo et al., 2026; AlSuhaimi et al., 2026; Marriam & Khalid, 2026). Scaling introduces gradients in mixing, temperature and pH, and these translate into batch-to-batch variation in size, charge, ligand density and drug loading (Akwo et al., 2026; AlSuhaimi et al., 2026). Because small structural differences can swing toxicity and efficacy, tight Chemistry, Manufacturing and Controls (CMC) are essential (Kanipandian et al., 2026; Payam & Lionadi, 2026).

Regulation, finally, remains genuinely unsettled (Bhukta et al., 2026; Tiwari et al., 2026). Multifunctional nanomedicines that combine targeted delivery, responsive triggers and imaging probes are often treated as drug-device combination products (Bhukta et al., 2026). Agencies such as the US FDA and the European EMA must then evaluate them across separate drug and device pathways, demanding extensive safety, clearance and immunogenicity data (Kanipandian et al., 2026; Tiwari et al., 2026). Standardised characterisation, continuous microfluidic manufacturing and early regulatory engagement are widely seen as the levers most likely to speed translation (Akwo et al., 2026; Marriam & Khalid, 2026).

3. Methods

3.1 Study design and reporting framework

This work was conducted as a structured narrative review of next-generation nanomedicine and its supporting technologies for personalised healthcare. Because the subject spans several disciplines, from synthetic chemistry and microfabrication to computational modelling and clinical oncology, a narrative synthesis was chosen over a strictly quantitative meta-analysis, which would not have accommodated such heterogeneous evidence. To keep the process transparent and reproducible, the review was nonetheless organised along the lines recommended for literature-based syntheses indexed in PubMed and related databases, with explicit, pre-specified steps for source identification, screening, data extraction and thematic synthesis (Boisseau & Loubaton, 2011; Fornaguera & García-Celma, 2017).

3.2 Information sources and search strategy

Peer-reviewed literature was identified through systematic searches of PubMed/MEDLINE and major indexed journal collections in nanotechnology and biomedical engineering, complemented by hand-searching the reference lists of retrieved articles. The search combined controlled vocabulary with free-text terms grouped into four conceptual blocks: (1) carrier design, using terms such as "nanomedicine", "nanoparticle", "stimuli-responsive", "chemo-biochemical convergence", "EPR effect" and "targeted drug delivery"; (2) physical sensing vectors, using "quantum biosensor", "organ-on-a-chip", "BioMEMS", "MEMS" and "Internet of Bodies"; (3) computational integration, using "multi-omics", "artificial intelligence", "machine learning", "digital twin" and "PBPK"; and (4) translation, using "protein corona", "GMP manufacturing", "nanotoxicity" and "regulatory". Terms within each block were combined with the Boolean operator OR, and the four blocks were then combined with AND.

3.3 Eligibility criteria

Records were eligible if they were peer-reviewed primary studies or reviews, written in English, that addressed one or more of the four thematic blocks in the context of human disease. Priority was given to sources published between 2011 and 2026 so as to capture both the foundational framing of personalised nanomedicine and the most recent technological advances. Articles were excluded if they lay outside the biomedical scope of the review, were not available in full text, or did not report sufficient methodological detail for their claims to be appraised. No restriction was placed on study design, given the conceptual breadth of the field.

3.4 Study selection

Screening proceeded in two stages. Titles and abstracts were first examined against the eligibility criteria to remove clearly irrelevant records. The full texts of the remaining articles were then assessed in detail, and those meeting all criteria were retained for synthesis. At each stage, decisions were documented and uncertainties resolved by re-reading the full text against the pre-specified criteria, so that the selection could be retraced by an independent reader.

3.5 Data extraction

A standardised extraction template was applied to every included source. For each record, the following were recorded where available: the technological platform or mechanism described; the chemical and structural engineering involved; the biological target, trigger or physiological interface; reported measures of efficacy, safety or analytical performance, including quantitative values such as delivery efficiency, release kinetics, sensor sensitivity and manufacturing variability; the principal limitations noted by the authors; and the disease context. Extracted quantitative figures are reported in the original units given by the source authors.

3.6 Synthesis and construction of tables and figures

Extracted data were grouped into four thematic domains corresponding to the structure of this review: targeting and stimulus-responsive delivery; physical and bio-engineering vectors; computational integration; and disease-specific translation with its bottlenecks. Within each domain, findings were compared across sources to identify convergent evidence, quantitative benchmarks and unresolved disagreements. The synthesis was then condensed into four summary tables (Tables 1-4) and four schematic figures (Figures 1-4), each cross-referenced to its primary sources. The figures were prepared as original schematic representations; they illustrate relationships described in the cited literature and do not reproduce copyrighted material. No statistical pooling was performed, consistent with the narrative design.

3.7 Reproducibility statement

All sources underpinning this review are listed in full in the bibliography with their digital object identifiers (DOIs) where available, so that any reader can retrieve the primary material and reconstruct the evidence base. Because the method relies on documented search terms, explicit eligibility criteria and a standardised extraction template rather than on proprietary data, the review can be repeated or updated by others following the steps described above.

4. Comparative Performance and Translational Readiness of Next-Generation Nanomedicine

Pulling the extracted evidence together, four result domains emerged, and they map onto the four themes that organise this review: the delivery performance of chemo-biochemical convergence against older paradigms; the sensing capability of quantum-OoC and BioMEMS platforms; the predictive accuracy of AI-driven digital twins; and disease-specific efficacy alongside the resolution of biological bottlenecks (Chowdhury et al., 2026; Marriam & Khalid, 2026).

4.1 Delivery efficiency and on-demand release of chemo-biochemical convergence

When the delivery data are placed side by side, the advantage of hierarchical, multi-stage platforms over first-generation passive systems is hard to miss [Table 1]. Passive EPR-based accumulation, as noted earlier, tends to deposit less than 1-8% of the injected dose in tumour tissue, a figure that reflects vascular heterogeneity, high interstitial pressure and dense stroma rather than any single failing (Akwo et al., 2026; Payam & Lionadi, 2026). Adding active ligands, whether anti-HER2 or anti-EGFR antibodies, RGD and iRGD peptides, or aptamers, clearly improves receptor-mediated uptake, yet active targeting on its own stays vulnerable to premature clearance and to ligand masking by the protein corona (Marriam & Khalid, 2026; Payam & Lionadi, 2026). That residual vulnerability is, in a sense, what convergence was designed to address [Figure 1].

What the release data show is that the benefit is conditional, and it depends on the trigger. pH-responsive systems, for example magnetic iron oxide particles or poly(amidoamine) dendrimers linked through acid-labile hydrazone or imine bonds, stay fairly quiet at blood pH 7.4, leaking only around 13-25% of their cargo in transit, then release perhaps 60-80% once inside the acidic endolysosome over a span of roughly 5-70 hours (Marriam & Khalid, 2026). Redox-responsive designs behave almost like a second gate: disulfide-linked gold or mesoporous organosilica carriers exploit the thousand-fold glutathione gradient between the extracellular space (about 2-20 micromolar) and the cytosol (0.5-10 millimolar), releasing more than half of their doxorubicin inside the cell while keeping background leakage under 20% (AlSuhaimi et al., 2026; Marriam & Khalid, 2026). Enzyme-responsive linkers cleaved by matrix metalloproteinases (MMP-2/9) add yet another layer, degrading matrix locally and timing release to the tumour itself (Marriam & Khalid, 2026). None of this is purely experimental: in PEGylated liposomal doxorubicin (Doxil), the same logic cuts cardiotoxicity by something like 70-80% relative to free drug (Payam & Lionadi, 2026). Table 1 lays out these mechanisms and their trade-offs in full.

4.2 Physical and bio-engineering performance: quantum-OoC and BioMEMS sensing

The sensing results tell a similar story of incremental, physics-enabled gains [Table 2]. Conventional organ-on-a-chip read-outs still lean on endpoint fluorescent staining, which photobleaches and interrupts perfusion, so embedding quantum sensors directly into the microchannels (typically 50-500 micrometres high) is less a refinement than a change of method (Preetam, 2026) [Figure 2]. NV-centre diamond magnetometry is the clearest case. Working through optically detected magnetic resonance at the roughly 2.87 GHz zero-field splitting, near-surface NV ensembles reach magnetic sensitivities approaching picotesla per root-hertz with sub-100 nm resolution, enough to record action-potential propagation in cardiac or neural microtissue without inserting a single electrode (Preetam, 2026).

Quantum dots cover the chemical side of the same problem. Size-tunable between 2 and 20 nm, they use excitonic Forster resonance energy transfer to report local pH, oxygen tension and millikelvin thermal fluctuations across three-dimensional tumour spheroids, resolving metabolic heterogeneity under continuous flow (Akwo et al., 2026; Preetam, 2026). At the scale of the whole body, the story shifts from precision to persistence: flexible MEMS, epidermal electronic tattoos and carbon-nanotube or graphene patches track EEG, ECG and EMG along with sweat and interstitial-fluid biomarkers, and when they drive closed-loop microneedle arrays they can administer drug in real time, which is much of what point-of-care and IoB deployment actually requires (Marinescu et al., 2025; Reddy et al., 2024). Table 2 details each platform's working principle, capability and technology-readiness level.

4.3 Predictive performance of multi-omics, AI and medical digital twins

On the computational side, the consistent finding is that modelling turns formulation from guesswork into something closer to prediction, though not yet into certainty [Table 3]. Machine-learning architectures, among them artificial neural networks, random forests and convolutional deep-learning models, forecast critical quality attributes such as hydrodynamic diameter, polydispersity index, zeta potential and encapsulation efficiency with useful accuracy (Deshmukh & Yadav, 2025; Laddha et al., 2026). In preclinical work, AI-optimised formulations have reportedly raised tumour uptake by up to about 30% over unoptimised controls, which is not trivial (Deshmukh & Yadav, 2025). Multi-omics data feed the same pipeline, matching ligands to overexpressed receptors and nucleic-acid cargo, siRNA or CRISPR-Cas9, to the mutated transcripts that actually drive a given tumour (Akwo et al., 2026).

Medical digital twins sit at the end of this chain [Figure 3]. By fusing PBPK differential models with data-driven AI layers and feeding them live BioMEMS signals and quantitative PET or MRI imaging, a twin can simulate vascular transport, corona evolution, biodistribution and organ-specific clearance, and so allow virtual dose optimisation and toxicity screening before any drug is given (Chowdhury et al., 2026). The caveat is substantial, and worth stating plainly: by one assessment roughly 98% of published healthcare digital twins remain at proof-of-concept stage and have not been validated prospectively, which is a long way from regulatory acceptance (Chowdhury et al., 2026). Table 3 compares these frameworks and their computational limitations.

4.4 Translational application in high-burden diseases and mitigation of bottlenecks

Finally, when these technologies are brought to bear on specific diseases, the pattern is one of real mechanistic progress shadowed by unresolved delivery and safety questions [Table 4]. Cuproptosis in hepatocellular carcinoma is the most striking example [Figure 4]. Exploiting the altered copper handling and high TCA-cycle activity of HCC cells, copper-based nanoplatforms, CuS nanocrystals, CuO nanoparticles and copper metal-organic frameworks, deliver a concentrated intracellular copper load; driven by ferredoxin-1 (FDX1) reduction, the released Cu(I) binds lipoylated mitochondrial proteins, chiefly DLAT, triggering protein aggregation, loss of iron-sulfur clusters, proteotoxic stress and selective cuproptotic death (Labhade & Pihulkar, 2026).

In CNS disease the mechanics are different but the logic is the same. Surface-engineered LNPs, MSNs and membrane-coated constructs negotiate the blood-brain barrier's tight junctions and P-glycoprotein efflux, and receptor-mediated transcytosis combined with MR-guided focused ultrasound can push temozolomide, paclitaxel or CRISPR payloads into glioblastoma and Alzheimer's models (Mazahir, 2026). The bottlenecks, meanwhile, are being chipped away rather than solved outright: pre-coating carriers with zwitterionic shells or patient-derived membranes blunts the Vroman-driven protein corona and its reticuloendothelial clearance (Akwo et al., 2026; AlSuhaimi et al., 2026), while a move from batch synthesis to continuous microfluidic manufacturing brings batch-to-batch variation below a 10% coefficient of variation, which is roughly what GMP and CMC expectations demand (Akwo et al., 2026). Table 4 sets out these applications, their preclinical status and the regulatory requirements that remain.

5. Reconciling Engineering Promise with Clinical Reality

If there is a single thread running through the evidence assembled here, it is that next-generation nanomedicine has become extraordinarily capable at the level of mechanism while remaining stubbornly difficult to translate. The four domains examined, convergent delivery, physical sensing, computational modelling and disease-specific application, each show the same shape: a steep rise in sophistication, followed by a plateau where biological complexity and regulatory caution take over (Marriam & Khalid, 2026; Payam & Lionadi, 2026). It seems worth dwelling on why that shape recurs, rather than simply cataloguing the advances again.

5.1 Convergence works, but conditionally

The delivery data in Table 1 make a reasonably strong case that chemo-biochemical convergence is more than a slogan [Table 1]. Layering stimulus-responsive gates onto actively targeted carriers does appear to raise the therapeutic index, and the Doxil example, with its 70-80% reduction in cardiotoxicity, shows the principle already paying off in an approved product (Payam & Lionadi, 2026). And yet the benefit is conditional in a way that is easy to understate. Each added trigger, pH, redox, enzymatic, assumes a microenvironment that is itself heterogeneous, so a gate tuned to an endolysosomal pH or a cytosolic glutathione gradient will behave differently from tumour to tumour and patient to patient (Marriam & Khalid, 2026) [Figure 1]. The convergence that solves the EPR problem, in other words, reintroduces variability of its own, which may be one reason elegant preclinical constructs so often lose their edge in trials.

5.2 Sensing precision against clinical practicality

A comparable tension runs through the physical vectors [Table 2]. The quantum-OoC platforms summarised in Figure 2 deliver genuinely remarkable precision, contactless action-potential recording at picotesla sensitivity is not a small achievement, but much of that performance currently depends on controlled laboratory conditions (Preetam, 2026) [Figure 2]. BioMEMS and IoB

Figure 3. The computational loop linking multi-omics, artificial intelligence and the medical digital twin. Workflow by which patient data are converted into personalised, predictive therapy. A patient data layer (genomics, transcriptomics, proteomics, metabolomics, electronic health records, PET/MRI imaging and BioMEMS/IoB streams) feeds two complementary models: an AI/ML formulation-design module that predicts particle size, zeta potential, polydispersity and encapsulation efficiency, and a physiologically based pharmacokinetic (PBPK) module describing absorption through clearance. Machine learning estimates hard-to-measure PBPK parameters such as protein-corona binding and clearance. The two converge in a continuously synchronised medical digital twin that performs in silico dosing and forecasts biodistribution and toxicity before administration; sensor and imaging feedback then update the twin. The caption notes the central caveat that most published healthcare digital twins remain proof-of-concept and lack prospective clinical validation.

Figure 4. Disease-specific applications of nanomedicine and the translational bottlenecks they must clear. Summary of two high-burden applications and their shared translational constraints. (A) In hepatocellular carcinoma, copper-based nanoplatforms (CuS, CuO, Cu-MOFs, liposomal copper) release intracellular copper that, via FDX1 reduction, binds lipoylated DLAT of the TCA cycle, causing iron-sulfur-cluster loss, proteotoxic stress and cuproptotic death, with off-target hepatotoxicity as the principal risk. (B) In central nervous system disease, mesoporous silica nanoparticles, lipid nanoparticles and membrane-coated carriers decorated with transferrin, lactoferrin or LDL-receptor ligands cross the blood-brain barrier by receptor-mediated transcytosis and focused-ultrasound opening to deliver temozolomide, paclitaxel, siRNA or CRISPR-Cas9 to glioblastoma and Alzheimer's targets. (C) Four linked bottlenecks (protein corona, GMP scale-up, safety/CMC and regulation) and their engineering mitigations stand between bench prototype and a reproducible, regulated bedside product.

devices sit at the other end of the spectrum: more robust, closer to deployment, but coarser in what they measure (Marinescu et al., 2025; Reddy et al., 2024). The field has, so far, not fully reconciled the two. Bridging laboratory-grade quantum sensing with wearable-grade durability is less a materials problem than a systems-integration one, and it is probably where the next real gains lie.

5.3 Digital twins and the validation gap

The computational results deserve the most caution, and here I think the literature is admirably candid about its own limits [Table 3]. Medical digital twins promise something close to in silico clinical trials, dosing tested, toxicity forecast, response predicted, all before the patient is exposed (Chowdhury et al., 2026) [Figure 3]. The finding that around 98% of published healthcare twins remain unvalidated is therefore not a footnote but the central qualifier (Chowdhury et al., 2026). A model that has not been tested prospectively cannot responsibly guide dosing, however sophisticated its PBPK-AI architecture. The hybrid approaches that use ML to estimate hard-to-measure parameters such as corona binding and clearance are promising precisely because they could, in time, make these twins falsifiable against real data (Chowdhury et al., 2026; Deshmukh & Yadav, 2025).

5.4 Disease applications and the persistence of biological barriers

The disease-specific work shows both how far mechanism has come and how resistant the body remains [Table 4]. Cuproptosis is a genuinely novel death pathway, and exploiting the copper dependence of hepatocellular carcinoma is a clever piece of metabolic targeting (Labhade & Pihulkar, 2026) [Figure 4]. But the same copper that kills tumour cells poses an off-target hepatotoxicity risk, which pushes the problem back toward biomarker-guided patient selection rather than away from it (Labhade & Pihulkar, 2026). The blood-brain barrier tells an even older story: receptor-mediated transcytosis and focused ultrasound help, yet CNS delivery efficiency stays low and the inorganic cores that make some carriers effective raise their own neurotoxicity questions (Mazahir, 2026). Progress here is real but incremental, and honesty about that pace matters.

5.5 Translational bottlenecks as the rate-limiting step

Taken together, the bottlenecks reviewed in Table 4, protein corona dynamics, manufacturing scale-up, safety and regulation, look less like separate hurdles than like a single, linked constraint on translation (Akwo et al., 2026; AlSuhaimi et al., 2026). The protein corona undermines the very targeting that convergence depends on; scale-up variability threatens the reproducibility that regulators require; and the drug-device character of these products strains frameworks built for simpler agents (Payam & Lionadi, 2026; Tiwari et al., 2026). The encouraging point is that the proposed remedies, continuous microfluidic manufacturing, standardised characterisation, patient-specific corona profiling and early engagement with the FDA and EMA, are mutually reinforcing (Akwo et al., 2026; Marriam & Khalid, 2026). Addressing them as a system, rather than piecemeal, is probably the single most important determinant of whether the mechanistic gains described here reach patients.

5.6 Limitations of this study

Some caveats about this review itself are in order. Its narrative design, chosen deliberately for a multidisciplinary field, means that evidence was synthesised qualitatively rather than pooled statistically, so the quantitative benchmarks reported, delivery percentages, release ranges, sensor sensitivities, are drawn from heterogeneous sources and should be read as indicative rather than definitive. The emphasis on recent literature, while appropriate for a fast-moving field, may underweight older foundational work, and the reliance on published reports inevitably carries the field's own tendency toward positive results. These limits do not undermine the central argument, but they do bound how firmly it can be stated.

5.7 Future directions

Looking ahead, the most valuable work may not be the next novel material at all. Prospective validation of digital twins, standardised and ideally patient-specific protein-corona assays, continuous manufacturing with real-time quality control, and regulatory pathways designed for combination products would, between them, do more to move the field than another generation of carriers (Chowdhury et al., 2026; Payam & Lionadi, 2026). The engineering, on the evidence gathered here, is largely in hand. What remains is the less glamorous work of proving, making and regulating it well enough for routine care.

6. Conclusion

Next-generation nanomedicine has matured from simple drug formulation into a convergent discipline in which

Table 3. Computational integration: multi-omics, artificial intelligence and digital twins. The table summarises the principal computational frameworks that underpin predictive, personalised nanomedicine. For each framework it lists the data inputs and algorithmic architecture, the core operational capability in nanomedicine, the clinical and translational application, and the balance of strengths against computational limitations. Primary supporting sources are given in the final column.

Table 4. Translational disease applications, biological bottlenecks and regulatory pathways. The table maps the leading disease applications and translational challenges of next-generation nanomedicine. For each entry it sets out the mechanistic basis and biological interfaces, the translational nanomedicine strategy, the preclinical efficacy and clinical status, and the principal bottlenecks and regulatory requirements that remain. Primary supporting sources are listed in the final column.

chemistry, physics, computation and biology meet at the nanoscale. The evidence synthesised here shows that stimulus-responsive, ligand-directed carriers now deliver drugs more selectively than passive EPR-based systems; that quantum biosensors, organ-on-a-chip platforms and BioMEMS enable continuous, label-free monitoring; and that multi-omics, artificial intelligence and digital twins are beginning to make therapy genuinely predictive and personal. Yet the same evidence is candid about the distance still to travel. Protein corona formation, batch-to-batch variability, incompletely understood long-term toxicity, and regulatory frameworks ill-suited to drug-device combinations continue to separate preclinical promise from clinical practice, and most digital twins remain unvalidated. The field's next decisive gains are therefore likely to come not from new materials but from standardised characterisation, prospective validation, continuous manufacturing and early regulatory engagement. Treated as a connected system, these challenges are solvable, and solving them is what will carry personalised nanomedicine to the bedside.

References